Endo International plc

NASDAQ:ENDP  
0.38
-0.01 (-3.62%)
4:07:34 PM EDT: $0.37 -0.01 (-1.81%)
Products, Regulatory, Other Pre-Announcement

Endo International Executes Agreement With TLC To Commercialize Phase 3 Orthopedic Product For Treatment Of Osteoarthritis Knee Pain

Published: 06/13/2022 10:43 GMT
Endo International plc (ENDP) - Endo Executes Agreement With Tlc to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain.
Endo International Plc - Endo Ventures Limited (evl) Has Executed an Agreement With Taiwan Liposome Company, Ltd.
Endo International Plc - Under Terms of Agreement, Tlc Will Primarily Be Responsible for Development of Product.
Endo International Plc - Upfront Payment of $30 Million Will Be Expensed in Q2 As Acquired In-process Research and Development.
Endo International Plc - This Expense Was Not Reflected in Endo's Q2 2022 Financial Guidance Provided on May 5, 2022.
Endo International Plc - Endo Currently Expects to Launch Differentiated Branded Product in United States in 2025.